Abstract
Background: Lung cancer patients have a higher chance of getting infected and showing severe outcomes from coronavirus disease 2019 (COVID-19). This infection influences the respiratory system, albeit other organs are also involved with high risk related to health. The blend of COVID-19 disease and lung cancer predicts a higher mortality rate and more serious clinical results.
Objective: This research reports the Systematic Review and Meta-analysis correlation between COVID-19 patients with lung cancer and comprehensive proof with regards to the mortality of these patients.
Methods: A systematic review and meta-analysis were planned to evaluate the data from a PubMed systematic search on Lung Cancer Patients reported by COVID-19, as well as an efficient literature review and information research from 2019 to 2021. Results: 22 out of 3639 review and research literature assessments were gathered, and 10951 patients were COVID +ve and suffering from cancer, with 21% of the patients suffering from SCLC and NSCLC, and lung cancer accounting for 6% of the mortality.
Conclusion: Lung cancer patients who are suffering from COVID-19 additionally reflected the seriousness of the illness and higher rates of intensive care unit confirmations and mechanical ventilation. COVID-19 in patients with lung cancer is related to extreme disease and expanded mortality compared with patients with different tumours. There is conflicting proof of explicit lung cancer therapies' results. Until more conclusive data is available, lung cancer-coordinated therapy should be restarted as soon as possible in mild to moderate cases to avoid decline and cancer-related mortality.
Keywords: COVID-19, Lung Cancer, Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC), respiratory system, tumours
Graphical Abstract
[1]
Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: What we know. Int J Infect Dis 2020; 94: 44-8.
[http://dx.doi.org/10.1016/j.ijid.2020.03.004] [PMID: 32171952]
[http://dx.doi.org/10.1016/j.ijid.2020.03.004] [PMID: 32171952]
[2]
Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[3]
Yang D, Leibowitz JL. The structure and functions of coronavirus genomic 3′ and 5′ ends. Virus Res 2015; 206: 120-33.
[http://dx.doi.org/10.1016/j.virusres.2015.02.025] [PMID: 25736566]
[http://dx.doi.org/10.1016/j.virusres.2015.02.025] [PMID: 25736566]
[4]
COVID Live Update: 271,770,446 cases and 5,337,661 deaths from the coronavirus - worldometer. Available from: https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1 (Accessed on: December 15, 2021).
[5]
Lei H, Yang Y, Zhou W, et al. Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis. Lung Cancer 2021; 157: 60-5.
[6]
Liang X, Chen Y, Fan Y. Bioinformatics approach to identify common gene signatures of patients with coronavirus 2019 and lung adenocarcinoma. Environ Sci Pollut Res Int 2022; 29(15): 22012-30.
[http://dx.doi.org/10.1007/S11356-021-17321-9/TABLES/3] [PMID: 34775559]
[http://dx.doi.org/10.1007/S11356-021-17321-9/TABLES/3] [PMID: 34775559]
[7]
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61(4): 212-36.
[http://dx.doi.org/10.3322/caac.20121] [PMID: 21685461]
[http://dx.doi.org/10.3322/caac.20121] [PMID: 21685461]
[8]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
[http://dx.doi.org/10.3322/caac.20107] [PMID: 21296855]
[http://dx.doi.org/10.3322/caac.20107] [PMID: 21296855]
[9]
Parkin DM, Pisani P, Lopez AD, Masuyer E. At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. Int J Cancer 1994; 59(4): 494-504.
[http://dx.doi.org/10.1002/ijc.2910590411] [PMID: 7960219]
[http://dx.doi.org/10.1002/ijc.2910590411] [PMID: 7960219]
[10]
Guindon GE, Boisclair D. Past, current and future trends in tobacco use 2003. Available from: https://openknowledge.worldbank.org/handle/10986/13726 (Accessed on: December 21, 2021).
[11]
Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359(13): 1367-80.
[http://dx.doi.org/10.1056/NEJMra0802714] [PMID: 18815398]
[http://dx.doi.org/10.1056/NEJMra0802714] [PMID: 18815398]
[12]
SEER Cancer Statistics Review 1975-2008 - Previous Version - SEER Cancer Statistics. Available from: https://seer.cancer.gov/archive/csr/1975_2008/ (Accessed on: December 21, 2021).
[13]
Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, Eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. (3rd Edition Volume 10:.), WHO Classification of Tumours 2014.
[14]
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
[http://dx.doi.org/10.1016/S0092-8674(00)81683-9] [PMID: 10647931]
[http://dx.doi.org/10.1016/S0092-8674(00)81683-9] [PMID: 10647931]
[15]
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83(5): 584-94.
[http://dx.doi.org/10.1016/S0025-6196(11)60735-0] [PMID: 18452692]
[http://dx.doi.org/10.1016/S0025-6196(11)60735-0] [PMID: 18452692]
[16]
Zhang J, Fujimoto J, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014; 346(6206): 256-9.
[http://dx.doi.org/10.1126/science.1256930] [PMID: 25301631]
[http://dx.doi.org/10.1126/science.1256930] [PMID: 25301631]
[17]
Rogado J, Pangua C, Serrano-Montero G, et al. COVID-19 and lung cancer: A greater fatality rate? Lung Cancer 2020; 146: 19-22.
[http://dx.doi.org/10.1016/j.lungcan.2020.05.034] [PMID: 32505076]
[http://dx.doi.org/10.1016/j.lungcan.2020.05.034] [PMID: 32505076]
[18]
Luo J, Rizvi H, Preeshagul IR, et al. COVID-19 in patients with lung cancer. Ann Oncol 2020; 31(10): 1386-96.
[http://dx.doi.org/10.1016/j.annonc.2020.06.007] [PMID: 32561401]
[http://dx.doi.org/10.1016/j.annonc.2020.06.007] [PMID: 32561401]
[19]
Zhang H, Wang L, Chen Y, et al. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer 2020; 126(17): 4023-31.
[http://dx.doi.org/10.1002/cncr.33042] [PMID: 32573776]
[http://dx.doi.org/10.1002/cncr.33042] [PMID: 32573776]
[20]
Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov 2020; 10(6): 783-91.
[http://dx.doi.org/10.1158/2159-8290.CD-20-0422] [PMID: 32345594]
[http://dx.doi.org/10.1158/2159-8290.CD-20-0422] [PMID: 32345594]
[21]
Yarza R, Bover M, Paredes D, et al. SARS-CoV-2 infection in cancer patients undergoing active treatment: Analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer 2020; 135: 242-50.
[http://dx.doi.org/10.1016/j.ejca.2020.06.001] [PMID: 32586724]
[http://dx.doi.org/10.1016/j.ejca.2020.06.001] [PMID: 32586724]
[22]
Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: A multicentre, retrospective, cohort study. Lancet Oncol 2020; 21(7): 904-13.
[http://dx.doi.org/10.1016/S1470-2045(20)30310-7] [PMID: 32479787]
[http://dx.doi.org/10.1016/S1470-2045(20)30310-7] [PMID: 32479787]
[23]
Calles A, Aparicio MI, Alva M, et al. Outcomes of COVID-19 in patients with lung cancer treated in a tertiary hospital in Madrid. Front Oncol 2020; 10: 1777.
[http://dx.doi.org/10.3389/fonc.2020.01777] [PMID: 33042826]
[http://dx.doi.org/10.3389/fonc.2020.01777] [PMID: 33042826]
[24]
de Melo AC, Thuler LCS, da Silva JL, et al. Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute. PLoS One 2020; 15(10): e0241261.
[http://dx.doi.org/10.1371/journal.pone.0241261] [PMID: 33104715]
[http://dx.doi.org/10.1371/journal.pone.0241261] [PMID: 33104715]
[25]
Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov 2020; 10(7): 935-41.
[http://dx.doi.org/10.1158/2159-8290.CD-20-0516] [PMID: 32357994]
[http://dx.doi.org/10.1158/2159-8290.CD-20-0516] [PMID: 32357994]
[26]
Basse C, Diakite S, Servois V, et al. Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients. JNCI Cancer Spectr 2021; 5(1): a090.
[http://dx.doi.org/10.1093/jncics/pkaa090] [PMID: 33604509]
[http://dx.doi.org/10.1093/jncics/pkaa090] [PMID: 33604509]
[27]
Stroppa EM, Toscani I, Citterio C, et al. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). Future Oncol 2020; 16(20): 1425-32.
[http://dx.doi.org/10.2217/fon-2020-0369] [PMID: 32403946]
[http://dx.doi.org/10.2217/fon-2020-0369] [PMID: 32403946]
[28]
Joharatnam-Hogan N, Hochhauser D, Shiu KK, et al. Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: A multi-centre North London experience. Ther Adv Med Oncol 2020; 12: 1758835920956803.
[http://dx.doi.org/10.1177/1758835920956803] [PMID: 32968429]
[http://dx.doi.org/10.1177/1758835920956803] [PMID: 32968429]
[29]
Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among us patients with cancer and COVID-19 infection. JAMA Oncol 2021; 7(2): 220-7.
[http://dx.doi.org/10.1001/jamaoncol.2020.6178] [PMID: 33300956]
[http://dx.doi.org/10.1001/jamaoncol.2020.6178] [PMID: 33300956]
[30]
Aschele C, Negru ME, Pastorino A, et al. Incidence of SARS-CoV-2 infection among patients undergoing active antitumor treatment in Italy. JAMA Oncol 2021; 7(2): 304-6.
[http://dx.doi.org/10.1001/jamaoncol.2020.6778] [PMID: 33331862]
[http://dx.doi.org/10.1001/jamaoncol.2020.6778] [PMID: 33331862]
[31]
Pinato DJ, Zambelli A, Aguilar-Company J, et al. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov 2020; 10(10): 1465-74.
[http://dx.doi.org/10.1158/2159-8290.CD-20-0773] [PMID: 32737082]
[http://dx.doi.org/10.1158/2159-8290.CD-20-0773] [PMID: 32737082]
[32]
Tagliamento M, Agostinetto E, Bruzzone M, et al. Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2021; 163: 103365.
[http://dx.doi.org/10.1016/j.critrevonc.2021.103365] [PMID: 34052423]
[http://dx.doi.org/10.1016/j.critrevonc.2021.103365] [PMID: 34052423]
[33]
Calvo V, Fernandez-Cruz A, Nuñez B, et al. Cancer and SARS-CoV-2 Infection: A Third-Level Hospital Experience. Clin Epidemiol 2021; 13: 317-24.
[http://dx.doi.org/10.2147/CLEP.S308437]
[http://dx.doi.org/10.2147/CLEP.S308437]
[34]
Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: A multicentre, retrospective, cohort study. Artic Lancet Oncol 2020; 21(7): 893-903.
[http://dx.doi.org/10.1016/S1470-2045(20)30309-0]
[http://dx.doi.org/10.1016/S1470-2045(20)30309-0]
[35]
Rugge M, Zorzi M, Guzzinati S. SARS-CoV-2 infection in the Italian Veneto region: Adverse outcomes in patients with cancer. Nat Cancer 2020; 1(8): 784-8.
[http://dx.doi.org/10.1038/s43018-020-0104-9]
[http://dx.doi.org/10.1038/s43018-020-0104-9]
[36]
de Joode K, Dumoulin DW, Tol J, et al. Dutch Oncology COVID-19 consortium. Outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur J Cancer 2020; 141: 171-84.
[http://dx.doi.org/10.1016/j.ejca.2020.09.027] [PMID: 33161241]
[http://dx.doi.org/10.1016/j.ejca.2020.09.027] [PMID: 33161241]
[37]
Lee LYW, Cazier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: A prospective cohort study. Lancet Oncol 2020; 21(10): 1309-16.
[http://dx.doi.org/10.1016/S1470-2045(20)30442-3] [PMID: 32853557]
[http://dx.doi.org/10.1016/S1470-2045(20)30442-3] [PMID: 32853557]
[38]
Peng S, Huang L, Zhao B, et al. Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis. J Thorac Cardiovasc Surg 2020; 160(2): 585-592.e2.
[http://dx.doi.org/10.1016/j.jtcvs.2020.04.005] [PMID: 32414594]
[http://dx.doi.org/10.1016/j.jtcvs.2020.04.005] [PMID: 32414594]
[39]
Samson P, Ning MS, Shaverdian N, et al. Clinical and radiographic presentations of COVID-19 among patients receiving radiation therapy for thoracic malignancies. Adv Radiat Oncol 2020; 5(4): 700-4.
[http://dx.doi.org/10.1016/j.adro.2020.04.020] [PMID: 32395673]
[http://dx.doi.org/10.1016/j.adro.2020.04.020] [PMID: 32395673]
[40]
El-Osta H, Jani P, Mansour A, Rascoe P, Jafri S. Endobronchial ultrasound for nodal staging of patients with non-small-cell lung cancer with radiologically normal mediastinum: A meta-analysis. Ann Am Thorac Soc 2018; 15(7): 864-74.
[http://dx.doi.org/10.1513/AnnalsATS.201711-863OC] [PMID: 29684288]
[http://dx.doi.org/10.1513/AnnalsATS.201711-863OC] [PMID: 29684288]
[41]
Lamb C, Shojaee S, Maldonado F. American Association for Bronchology and Interventional Pulmonology (AABIP) statement on the use of bronchoscopy and respiratory specimen collection in patients with suspected or. Artic J Bronchol Interv Pulmonol 2020; 27(4): e52-4.
[http://dx.doi.org/10.1097/LBR.0000000000000681]
[http://dx.doi.org/10.1097/LBR.0000000000000681]
[42]
Greenberg A, Anand G, Sinclair G. Lung cancer treatment in COVID-19-positive patients: Guidelines and gestalt. JCO Oncol Pract 2020; 16(9): 615-7.
[http://dx.doi.org/10.1200/OP.20.00511] [PMID: 32780642]
[http://dx.doi.org/10.1200/OP.20.00511] [PMID: 32780642]
Related Journals
Article Metrics
7